# PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)

> **NCT00515593** · — · COMPLETED · sponsor: **Nycomed** · enrollment: 110 (actual)

## Conditions studied

- Postmenopause
- Osteoporosis

## Interventions

- **DRUG:** Parathyroid hormone (PTH) (Preotact)

## Key facts

- **NCT ID:** NCT00515593
- **Lead sponsor:** Nycomed
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-07
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515593, "PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00515593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*